Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW OKs Authorized Generics for Aimix, Cravit IV, Takepron; June Listing Eyed
February 16, 2018
- 20 Gx Makers Flock to Aimix, Sawai Earns Approval for Tamiflu Copy for June Listing
February 16, 2018
- MHLW Launches Startup Support Project
February 16, 2018
- MHLW Looked at Balance and Made Major Revision Plans for Drug Pricing: Official
February 14, 2018
- Label Revisions Ordered for Gardenia Fruit Kampo Agents, Stocrin
February 14, 2018
- Japan Cabinet Adopts Bill to Require Generic Use for Welfare Recipients
February 13, 2018
- Payers Give High Marks for “Bold” Pricing Reform, but Not Happy with PMP
February 8, 2018
- Chuikyo Submits Recommendation for FY2018 Reimbursement Policy Reform, Drug Pricing Package Enshrined
February 8, 2018
- MHLW Notifies of Revisions of Ministerial Ordinances to Prevent Distribution of Counterfeit Drugs
February 7, 2018
- Japan’s 1st Herceptin Biosimilar Clears MHLW Panel, Now in Line for March Approval for Gastric Cancer
February 5, 2018
- MHLW Panel Backs “Sakigake” Influenza Drug; Possibility of Accelerated Approval and Listing Unclear
February 5, 2018
- MHLW Cautions on Hepatitis E Virus Infection due to Blood Products for Transfusion
February 2, 2018
- MHLW Panel Calls for Single-Product, Single-Price Transactions for Blood Products
February 2, 2018
- Proper Use of Ethical Moisturizing Agents Added to Supplementary Opinion for FY2018 Reimbursement Reform: Chuikyo
February 1, 2018
- Drug Pricing Reform Draws Mixed Opinions: Public Comments
February 1, 2018
- Drug Makers Looking to Adopt Continuous Manufacturing, Anticipating 30-40% Lower Production Costs: PMDA Official
January 31, 2018
- MHLW to Create Framework for Announcing Results of Clinical Research in Tandem with Enforcement of Clinical Research Law
January 29, 2018
- Chuikyo to Continue Discussions on Drug Pricing Reform “After Verifying Impact on Stakeholders”; Further Discussions on Essential Drugs
January 29, 2018
- Chuikyo Discusses Hirudoid, Gx at 2nd Review Round for FY2018 Fee Schedule Revision
January 29, 2018
- MHLW Panel Backs Novo’s Semaglutide after Recommendation Hold
January 29, 2018
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…